ProCE Banner Activity

Considering the Continuation of Bictegravir/FTC/TAF in Pregnancy

Clinical Thought
Many patients are receiving BIC/FTC/TAF as an initial ART regimen, but what should you do if these patients become pregnant?

Released: October 15, 2021

Expiration: October 14, 2022

No longer available for credit.

Share

Faculty

William R. Short

William R. Short, MD, MPH, FIDSA

Associate Director of the HIV Clinical Trials Unit
Associate Professor of Medicine and Obstetrics and Gynecology
Division of Infectious Diseases
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Supporters

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

ViiV Healthcare

Faculty Disclosure

Primary Author

William R. Short, MD, MPH, FIDSA

Associate Director of the HIV Clinical Trials Unit
Associate Professor of Medicine and Obstetrics and Gynecology
Division of Infectious Diseases
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

William R. Short, MD, MPH, AAHIVS, has disclosed that he has received fees for non-CME/CE services from Janssen and consulting fees from ViiV.